Loading organizations...
Eleven operates as a venture capital fund, investing in early-stage technology companies across Europe, with a pronounced focus on Central Eastern Europe. The firm provides essential capital and strategic guidance, enabling local founders to develop and scale their innovations. Its fundamental approach is empowering entrepreneurs to achieve significant global market presence.
Established in 2012 by Daniel Tomov and Ivaylo Simov, Eleven originated from a conviction regarding Central Eastern Europe's substantial, yet often underestimated, technological capabilities. Their founding insight emphasized a hands-on investment model that extended beyond mere funding, aiming to cultivate robust companies directly from the region. This philosophy drives their portfolio engagement.
Eleven primarily serves ambitious early-stage technology companies and their founders, whom it labels "local heroes," predominantly within Central Eastern Europe. The fund’s long-term vision is to elevate these regional businesses to global recognition and influence. It strives to foster a dynamic ecosystem of impactful enterprises, powered by local expertise, capable of worldwide contributions.
The Eleven Fund has 2 tracked investments across 2 companies. The latest tracked deal is $120.0M Series C in Escient Pharmaceuticals in November 2022.
| Date | Company | Round | Lead Investor(s) | Co-Investor(s) |
|---|---|---|---|---|
| Nov 1, 2022 | Escient Pharmaceuticals | $120.0M Series C | Abingworth, Forge Life Science Partners, NEA | 5AM Ventures, Access Biotechnology, Atlas Venture, Carol Gallagher, Robert Garland, Nextech Invest, OrbiMed, Osage University Partners, Sanofi Ventures, The Column Group, Altitude Life Science Ventures, Avego Bioscience Capital, Cowen Healthcare Investments, PFM Health Sciences, Redmile Group |
| Jul 19, 2022 | Alleaves | $40.0M Series A | The Eleven Fund | — |